Deyev, S. M., Xu, T., Liu, Y., Schulga, A., Konovalova, E., Garousi, J., Rinne, S. S., Larkina, M., Ding, H., Gräslund, T., Orlova, A., Tolmachev, V., & Vorobyeva, A. Influence of the Position and Composition of Radiometals and Radioiodine Labels on Imaging of Epcam Expression in Prostate Cancer Model Using the DARPin Ec1 //Cancers.– 2021. – Vol. 13. – No. 14. – P. 3589. DOI:10.3390/cancers13143589 https://www.mdpi.com/2072-6694/13/14/3589
Bragina, O., Chernov, V., Schulga, A., Konovalova, E., Garbukov, E., Vorobyeva, A., Orlova, A., Tashireva, L., Sorensen, J., Zelchan, R., Medvedeva, A., Deyev, S., & Tolmachev, V. Phase I trial of 99mTc-(HE)3-G3, a DARPin-based probe for imaging of HER2 expression in breast cancer //Journal of nuclear medicine: official publication, Society of Nuclear Medicine.– 2021. – jnumed.121.262542. Advance online publication. DOI:10.2967/jnumed.121.262542 https://jnm.snmjournals.org/content/early/2021/08/12/jnumed.121.262542
Xu, T., Vorobyeva, A., Schulga, A., Konovalova, E., Vorontsova, O., Ding, H., Gräslund, T., Tashireva, L. A., Orlova, A., Tolmachev, V., & Deyev, S. M. Imaging-Guided Therapy Simultaneously Targeting HER2 and EpCAM with Trastuzumab and EpCAM-Directed Toxin Provides Additive Effect in Ovarian Cancer Model //Cancers.– 2021. – Vol. 13. – No. 16. – P. 3939. DOI:10.3390/cancers13163939 https://www.mdpi.com/2072-6694/13/16/3939
Rinne, S.S.; Leitao, C.D.; Abouzayed, A.; Vorobyeva, A.; Tolmachev, V.; Ståhl, S.; Löfblom, J.; Orlova, A. HER3 PET Imaging: 68Ga-Labeled Affibody Molecules Provide Superior HER3 Contrast to 89Zr-Labeled Antibody and Antibody-Fragment-Based Tracers. Cancers. – 2021. – Vol. 13.– P. 4791. DOI:10.3390/cancers13194791 https://www.mdpi.com/2072-6694/13/19/4791
Rinne, S. S., Orlova, A., & Tolmachev, V. PET and SPECT Imaging of the EGFR Family (RTK Class I) in Oncology //International journal of molecular sciences. – 2021. – Vol. 22. – No. 7. – P. 3663. DOI: 10.3390/ijms22073663 https://www.mdpi.com/1422-0067/22/7/3663
Liu, Y., Vorobyeva, A., Xu, T., Orlova, A., Loftenius, A., Bengtsson, T., Jonasson, P., Tolmachev, V., & Frejd, F. Y. Comparative Preclinical Evaluation of HER2-Targeting ABD-Fused Affibody® Molecules 177Lu-ABY-271 and 177Lu-ABY-027: Impact of DOTA Position on ABD Domain //Pharmaceutics.– 2021. – Vol. 13. – No. 6. – P. 839. DOI:10.3390/pharmaceutics1306083 https://pubmed.ncbi.nlm.nih.gov/34200197
Bragina, O., von Witting, E., Garousi, J., Zelchan, R., Sandström, M., Orlova, A., Medvedeva, A., Doroshenko, A., Vorobyeva, A., Lindbo, S., Borin, J., Tarabanovskaya, N., Sörensen, J., Hober, S., Chernov, V., & Tolmachev, V. Phase I Study of 99mTc-ADAPT6, a Scaffold Protein-Based Probe for Visualization of HER2 Expression in Breast Cancer //Journal of nuclear medicine. – 2021. – Vol. 62. – No. 4. – P. 493–499. DOI:10.2967/jnumed.120.248799 https://jnm.snmjournals.org/content/62/4/493
Oroujeni, M., Rinne, S.S., Vorobyeva, A., Loftenius, A., Feldwisch, J., Jonasson, P., Chernov, V., Orlova, A., Frejd, F.Y., Tolmachev, V. Preclinical Evaluation of 99mTc-ZHER2:41071, a Second-Generation Affibody-Based HER2-Visualizing Imaging Probe with a Low Renal Uptake //International Journal of Molecular Sciences. – 2021. – Vol. 22. – No. 2770. DOI:10.3390/ijms22052770 https://www.mdpi.com/1422-0067/22/5/2770
Oroujeni, M., Xu, T., Gagnon, K., Rinne, S.S., Weis, J., Garousi, J., Andersson, K.G., Löfblom, J., Orlova, A. and Tolmachev, V. Improves Imaging Contrast of EGFR Expression in Malignant Tumours Using DFO-ZEGFR:2377 Affibody Molecule //Pharmaceutics. – 2021. – Vol. 13. – No. 292. DOI: 10.3390/pharmaceutics13020292 https://www.mdpi.com/1999-4923/13/2/292
Ding, H., Xu, T., Zhang, J., Tolmachev, V., Oroujeni, M., Orlova, A., Gräslund, T., Vorobyeva, A. Affibody-Derived Drug Conjugates Targeting HER2: Effect of Drug Load on Cytotoxicity and Biodistribution //Pharmaceutics. – 2021. – Vol. 13. – No. 430. DOI: 10.3390/pharmaceutics13030430. https://www.mdpi.com/search?q=Affibody-Derived+Drug+&journal=pharmaceutics
Abouzayed, A., Rinne, S. S., Sabahnoo, H., Sörensen, J., Chernov, V., Tolmachev, V., Orlova, A. Preclinical Evaluation of 99mTc-Labeled GRPR Antagonists maSSS/SES-PEG2-RM26 for Imaging of Prostate Cancer //Pharmaceutics. – 2021. – Vol. 13. – No. 2. – P. 182. DOI: 10.3390/pharmaceutics13020182 https://www.mdpi.com/1999-4923/13/2/182
Rinne, S.S., Abouzayed, A., Gagnon, K., Tolmachev, V., Orlova, A. 66 Ga-PET-imaging of GRPR-expression in prostate cancer: production and characterization of [66 Ga] Ga-NOTA-PEG 2-RM26 //Scientific reports. – 2021. – Vol. 11. – No. 1. – P. 1-12. DOI: 10.1038/s41598-021-82995-7 https://pubmed.ncbi.nlm.nih.gov/33574368
Xu, T., Ding, H., Vorobyeva, A., Oroujeni, M., Orlova, A., Tolmachev, V., Gräslund, T. Drug conjugates based on a monovalent affibody targeting vector can efficiently eradicate HER2 positive human tumors in an experimental mouse model //Cancers. – 2021. – Vol. 13. – No. 1. – P. 85. DOI:10.3390/cancers13010085 https://www.mdpi.com/2072-6694/13/1/85
Tano, H., Oroujeni, M., Vorobyeva, A., Westerlund, K., Liu, Y., Xu, T., Vasconcelos, D., Orlova, A., Karlström, A.E., Tolmachev, V. Comparative Evaluation of Novel 177Lu-Labeled PNA Probes for Affibody-Mediated PNA-Based Pretargeting //Cancers. – 2021. – Vol. 13. – No. 3. – P. 500. DOI: 10.3390/cancers13030500 https://www.mdpi.com/2072-6694/13/3/500
Baun, C., Mitran, B., Rinne, S. S., Dam, J. H., Olsen, B. B., Tolmachev, V., Orlova, A. Thisgaard, H. Preclinical Evaluation of the Copper-64 Labeled GRPR-Antagonist RM26 in Comparison with the Cobalt-55 Labeled Counterpart for PET-Imaging of Prostate Cancer //Molecules. 2020. – Vol. 25. – No. 24. – P. 5993. DOI: 10.3390/molecules25245993 https://www.mdpi.com/1420-3049/25/24/5993
Abouzayed, A., Tano, H., Nagy, Á., Rinne, S.S., Wadeea, F., Kumar, S., Westerlund, K., Tolmachev, V., Karlström, A.E., Orlova, A. Preclinical evaluation of the grpr-targeting antagonist rm26 conjugated to the albumin-binding domain for grpr-targeting therapy of cancer //Pharmaceutics. – 2020. – Vol. 12. – No. 10. – P. 977. DOI: 10.3390/pharmaceutics12100977 https://www.mdpi.com/1999-4923/12/10/977
Tolmachev V., Orlova A., Sörensen J. The emerging role of radionuclide molecular imaging of HER2 expression in breast cancer //Seminars in Cancer Biology. – Academic Press, 2021. DOI: 10.1016/j.semcancer.2020.10.005 https://www.sciencedirect.com/science/article/
Garousi, J., von Witting, E., Borin, J., Vorobyeva, A., Altai, M., Vorontsova, O., Konijnenberg, M.W., Oroujeni, M., Orlova, A., Tolmachev, V. Hober, S. Radionuclide therapy using ABD-fused ADAPT scaffold protein: Proof of Principle //Biomaterials. – 2021. – Vol. 266. – P. 120381 DOI:10.1016/j.biomaterials.2020.120381 https://www.sciencedirect.com/science/article/pii/S014296122030627X
Leitao, C.D., Rinne, S.S., Altai, M., Vorontsova, O., Dunås, F., Jonasson, P., Tolmachev, V., Löfblom, J., Ståhl, S., Orlova, A. Evaluating the therapeutic efficacy of mono-and bivalent affibody-based fusion proteins targeting HER3 in a pancreatic cancer xenograft model //Pharmaceutics. – 2020. – Vol. 12. – No. 6. – P. 551. DOI: 10.3390/pharmaceutics12060551 https://www.mdpi.com/1999-4923/12/6/551
Vorobyeva, A., Bezverkhniaia, E., Konovalova, E., Schulga, A., Garousi, J., Vorontsova, O., Abouzayed, A., Orlova, A., Deyev, S., Tolmachev, V. Radionuclide molecular imaging of EpCAM expression in triple-negative breast cancer using the scaffold protein DARPin Ec1 //Molecules. – 2020. – Vol. 25. – No. 20. – P. 4719. DOI: 10.3390/molecules25204719 https://www.mdpi.com/1420-3049/25/20/4719
Vorobyeva, A., Konovalova, E., Xu, T., Schulga, A., Altai, M., Garousi, J., Rinne, S.S., Orlova, A., Tolmachev, V., Deyev, S. Feasibility of imaging epcam expression in ovarian cancer using radiolabeled darpin ec1 //International Journal of Molecular Sciences. – 2020. – Vol. 21. – No. 9. – P. 3310. DOI: 10.3390/ijms21093310 https://www.mdpi.com/1422-0067/21/9/3310/htm
Ding, H., Altai, M., Yin, W., Lindbo, S., Liu, H., Garousi, J., Xu, T., Orlova, A., Tolmachev, V., Hober, S., Gräslund, T. HER2-specific pseudomonas exotoxin a pe25 based fusions: Influence of targeting domain on target binding, toxicity, and in vivo biodistribution //Pharmaceutics. – 2020. – Vol. 12. – No. 4. – P. 391. DOI: 10.3390/pharmaceutics12040391 https://www.mdpi.com/1999-4923/12/4/391/htm
Tolmachev, V., Orlova, A. Affibody molecules as targeting vectors for PET imaging //Cancers. – 2020. – Vol. 12. – No. 3. – P. 651. DOI: 10.3390/cancers12030651 https://www.mdpi.com/2072-6694/12/3/651
Rinne, S.S., Leitao, C.D., Saleh-Nihad, Z., Mitran, B., Tolmachev, V., Ståhl, S., Löfblom, J., Orlova, A. Benefit of later-time-point PET imaging of her3 expression using optimized radiocobalt-labeled affibody molecules //International journal of molecular sciences. – 2020. – Vol. 21. – No. 6. – P. 1972. DOI: 10.3390/ijms21061972 https://www.mdpi.com/1422-0067/21/6/1972
Deyev, S.M., Vorobyeva, A., Schulga, A., Abouzayed, A., Günther, T., Garousi, J., Konovalova, E., Ding, H., Gräslund, T., Orlova, A., Tolmachev, V. Effect of a radiolabel biochemical nature on tumor-targeting properties of EpCAM-binding engineered scaffold protein DARPin Ec1 //International Journal of Biological Macromolecules. – 2020. – Vol. 145. – P. 216-225. DOI: 10.1016/j.ijbiomac.2019.12.147 https://www.sciencedirect.com/science/article/pii/S0141813019393808
Rinne, S.S., Xu, T., Leitao, C.D., Ståhl, S., Löfblom, J., Orlova, A., Tolmachev, V., Vorobyeva, A. Influence of residualizing properties of the radiolabel on radionuclide molecular imaging of HER3 using affibody molecules //International Journal of Molecular Sciences. – 2020. – Vol. 21. – No. 4. – P. 1312. DOI: 10.3390/ijms21041312
Altai, M., Vorobyeva, A., Tolmachev, V., Karlström, A.E., Westerlund, K. Preparation of Conjugates for Affibody-Based PNA-Mediated Pretargeting //Peptide Nucleic Acids. – Humana, New York, NY, 2020. – P. 283-304. DOI: 10.1007/978-1-0716-0243-0_18
Larkina, M.S., Ozerskaya, A.V., Podrezova, E.V., Belousov, M.V., Tolmachev, V., Zhdankin, V.V., Yusubov, M.S. Efficient Synthesis of ω-[18F]Fluoroaliphatic Carboxylic Esters and Acids for Positron Emission //European Journal of Organic Chemistry. – 2020. – P. 6375-6381. DOI: 10.1002/ejoc.202000934 https://chemistry-europe.onlinelibrary.wiley.com/doi/abs/10.1002/ejoc.202000934
Alhuseinalkhudhur, A., Lubberink, M., Lindman, H., Tolmachev, V., Frejd, F.Y., Feldwisch, J., Velikyan, I., Sörensen, J. Kinetic analysis of HER2-binding ABY-025 Affibody molecule using dynamic PET in patients with metastatic breast cancer //EJNMMI research. – 2020. – Vol. 10. – No. 1. – P. 1-10. DOI: 10.1186/s13550-020-0603-9 https://ejnmmires.springeropen.com/articles/10.1186/s13550-020-0603-9
Lundmark, F., Abouzayed, A., Mitran, B., Rinne, S.S., Varasteh, Z., Larhed, M., Tolmachev, V., Rosenström, U., Orlova, A. Heterodimeric radiotracer targeting PSMA and GRPR for imaging of prostate cancer—optimization of the affinity towards PSMA by linker modification in murine model //Pharmaceutics. – 2020. – Vol. 12. – No. 7. – P. 614. DOI: 10.3390/pharmaceutics12070614 https://www.mdpi.com/1999-4923/12/7/614
Bragina, O.D., Vorobyeva, A.G., Tolmachev, V.M., Orlova, A.M., Chernov, V.I., Deyev, S.M., Proshkina, G.N., Shulga, A.A., Larkina, M.S., Medvedeva, A.A., Zelchan, R.V. In vitro and in vivo evaluation of the radiochemical compound based on 99m technetium labelled DARPin9_29 for molecular visualization of malignancies overexpressing Her2/neu [In vitro и in vivo оценка радиохимического соединения на основе меченного 99m-Tc каркасного белка DARPin9_29 для молекулярной визуализации злокачественных образований с гиперэкспрессией Her2/neu] //Medical Radiology and Radiation Safety. – 2020. – Vol. 65. – No. 1. – P. 37-41. DOI: 10.12737/1024-6177-2020-65-1-37-41 https://medradiol.fmbafmbc.ru/journal_medradiol/abstracts/2020/1/37-41_Bragina_et_al.pdf
